(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.34% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.83%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,628,000,000.On average, 5 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,366,305,024,377, with the lowest TEVA revenue forecast at $19,217,072,161,584, and the highest TEVA revenue forecast at $19,561,469,809,886. On average, 5 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,463,929,861,715, with the lowest TEVA revenue forecast at $19,322,610,045,948, and the highest TEVA revenue forecast at $19,636,539,365,894.
In 2027, TEVA is forecast to generate $19,924,660,084,510 in revenue, with the lowest revenue forecast at $19,698,416,686,357 and the highest revenue forecast at $20,291,470,767,428.